Nasal mRNA Nanovaccine with Key Activators of Dendritic and MAIT Cells for Effective Against Lung Tumor Metastasis in Mice Model
Ang Li,Xushan Cai,Dong Li,Yimin Yu,Chengyu Liu,Jie Shen,Jiaqi You,Jianou Qiao,Feng Wang
DOI: https://doi.org/10.2147/ijn.s479741
IF: 7.033
2024-11-09
International Journal of Nanomedicine
Abstract:Ang Li, 1, &ast Xushan Cai, 2, &ast Dong Li, 1, &ast Yimin Yu, 1 Chengyu Liu, 1 Jie Shen, 1 Jiaqi You, 3 Jianou Qiao, 3 Feng Wang 4 1 Department of Laboratory Medicine, Shanghai Tongji Hospital, School of Medicine, School of Life Science and Technology, Tongji University, Shanghai, People's Republic of China; 2 Department of Clinical Laboratory, Shanghai Jiading Maternal and Child Health Hospital, Shanghai, People's Republic of China; 3 Department of Respiratory, Shanghai Ninth People's Hospital Affiliated Shanghai JiaoTong University School of Medicine, Shanghai, People's Republic of China; 4 Department of Thoracic Surgery, Shanghai Ninth People's Hospital Affiliated Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China &astThese authors contributed equally to this work Correspondence: Ang Li, Department of Laboratory Medicine, Shanghai Tongji Hospital, School of Medicine, School of Life Science and Technology, Tongji University, No. 389 Xincun Road, Shanghai, 200065, People's Republic of China, Email Feng Wang, Department of Thoracic Surgery, Shanghai Ninth People's Hospital Affiliated Shanghai Jiao Tong University School of Medicine, No. 639, Zhizaoju Road, Shanghai, 200011, People's Republic of China, Email Background: Lung metastasis is a leading cause of cancer-related death. mRNA-based cancer vaccines have been demonstrated to be effective at inhibiting tumor growth. Intranasal immunization has emerged as a more effective method of inducing local immune responses against cancer cells in the lungs. Methods: An innovative layered double hydroxide- and 5-OP-RU–based mRNA nanovaccine (Mg/Al LDH-5-OP-RU/mRNA) was synthesized via coprecipitation. The particle size distribution and zeta potential were measured, and the nanovaccine was observed by transmission electron microscopy. The functions and properties of the nanovaccine were evaluated via an mRNA-targeted delivery assay and measurement of dendritic cell (DC) and mucosa-associated invariant T (MAIT) cell maturation and activation. In addition, the cytotoxicity, antigen-specific T cell activation, cytokines, protective ability, and therapeutic ability of the nanovaccine were assessed in a mouse tumor model. Further, the immune cell composition was evaluated in tumors. Results: The Mg/Al LDH-5-OP-RU/mRNA nanovaccine was efficiently delivered into lung-draining mediastinal lymph nodes (MLNs), and it activated dendritic cells (DCs) and mucosa-associated invariant T (MAIT) cells after intranasal administration. Moreover, the optimized dual-activating mRNA nanovaccine efficiently transfected DC cells and expressed antigen proteins in DC cells. An HPV-associated tumor model revealed that the intranasal delivery of the Mg/Al LDH-5-OP-RU/E7 mRNA nanovaccine significantly prevented the lung metastasis of tumors and had a therapeutic effect on established metastatic tumor nodules in the lungs. Mechanistically, the enhanced activation of DC and MAIT cells induced by the Mg/Al LDH-5-OP-RU/E7 mRNA nanovaccine increased the production of immune-stimulating cytokines and decreased the secretion of immunosuppressive cytokines, which led to the expansion and activation of memory T cells targeting the E7 antigen, a reduction in the population of neutrophils, and differentiation of tumor -associated macrophages to the M1 phenotype in the lungs. Conclusion: These results highlight the potential of the innovative nasal mRNA nanovaccine for both preventing and treating tumor metastasis in the lungs. Keywords: mRNA nanovaccine, layered double hydroxide, 5-OP-RU, dendritic cells, Mucosa-associated invariant T cells, lung metastasis The majority of cancer-related fatalities are caused by the spread of cancer cells to distant parts of the body rather than the initial tumor. The incidence of lung metastasis in cancer patients ranges from 20% to 54%, making it a major contributor to morbidity and mortality in individuals with advanced cancer. 1 A viable strategy to inhibit lung metastasis may be to induce antitumor immunity against cancer cells that have migrated to the lungs. Intranasal immunization has emerged as a more effective method of inducing local immune responses in the lungs and activating pulmonary tissue-resident memory T cells, which can provide protection against tumor challenges. 2,3 On the basis of these traits, there is strong interest in developing nasal vaccines that can effectively stimulate local immune responses in the lungs to combat lung metastatic cancer. Given the remarkable efficacy demonstrated by mRNA vaccines in combating SARS-C -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology